Kilitch Drugs Limited, a leading pharmaceutical company specializing in the manufacturing and distribution of high-quality Parenteral, Injectables, Oral Solids, and Effervescent, announced its unaudited financial results for the quarter ended on 31 March 2025.

The company reported a 178% per cent year-on-year(Y-o-Y) remarkable rise in consolidated profit after tax (PAT) for the Q4 FY25 to Rs. 10.21 crore from Rs. 3.68 crore for the corresponding period previous year.

The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25, experiencing 37 per cent of Y-o-Y excellence growth from Rs. 44.81 crore in Q4FY24. The growth is achieved by continuous efforts to meet steady demand across globe and will continue further.

Consecutively, the company’s standalone PAT rose by 212% per cent, and revenue grew by 44 per cent to Rs 11.37 crore and Rs 181.58 crore recorded in Q4 FY25, respectively.

Commenting on the Q4FY25 performance, Mukund Mehta, the Managing Director, Kilitch Drugs said, “We witnessed significant growth in our performance for this year; revenue from operations grew by 44% and PAT increased by 212% on standalone basis as compared to Q4FY2024. We remain focused on driving sustainable growth and delivering strong returns for our stakeholders.”